ADReCS

Pharmaceutical Information

Drug Name	Prednisolone
Drug ID	BADD_D01831
Description	Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.[A187463] Prednisolone was granted FDA approval on 21 June 1955.[L9431]
Indications and Usage	Prednisolone is indicated to treat endocrine, rheumatic, and hematologic disorders; collagen, dermatologic, ophthalmic, respiratory, and gastrointestinal diseases; allergic and edematous states; and other conditions like tuberculous meningitis.[L9542]
Marketing Status	approved; vet_approved
ATC Code	A01AC04; A07EA01; C05AA04; D07AA03; D07XA02; H02AB06; R01AD02; S01BA04; S01CB02; S02BA03; S03BA02
DrugBank ID	DB00860
KEGG ID	D00472
MeSH ID	D011239
PubChem ID	5755
TTD Drug ID	D0D1SG
NDC Product Code	38779-0150; 64958-0097; 82298-104; 67296-1656; 50383-042; 59651-491; 63187-466; 0527-5406; 65089-0038; 50090-0655; 57582-004; 62135-437; 73534-505; 49452-5980; 82298-105; 82298-106; 60592-911; 60722-3001; 51927-0234; 22552-0052
UNII	9PHQ9Y1OLM
Synonyms	Prednisolone \| Predate \| Predonine \| Di-Adreson-F \| Di Adreson F \| DiAdresonF

Chemical Information

Molecular Formula	C21H28O5
CAS Registry Number	50-24-8
SMILES	CC12CC(C3C(C1CCC2(C(=O)CO)O)CCC4=CC(=O)C=CC34C)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Swelling	08.01.03.015	0.000426%		-
Swelling face	08.01.03.100; 10.01.05.018; 23.04.01.018	0.000531%		-
Swollen tongue	07.14.02.003; 10.01.05.015; 23.04.01.014	0.000210%		-
Syncope	02.11.04.015; 17.02.04.008; 24.06.02.012	-	-
Synovial cyst	15.04.02.002; 16.18.01.004	0.000052%		-
Synovitis	15.04.02.001	0.000140%		-
Systemic lupus erythematosus	10.04.03.004; 15.06.02.003; 23.03.02.006	0.000280%		-
Tachycardia	02.03.02.007	0.000734%		-
Tachycardia foetal	02.03.02.017; 18.03.02.005	0.000035%		-
Tachypnoea	22.02.01.014	0.000070%		-
Tearfulness	19.15.02.005	0.000035%		-
Telangiectasia	23.06.03.001; 24.03.03.003	0.000035%
Tendon disorder	12.01.07.019; 15.07.01.002	0.000070%		-
Tendon rupture	12.01.07.003; 15.07.01.008	-	-	-
Tendonitis	12.01.07.007; 15.07.01.003	0.000210%		-
Tenosynovitis	15.07.01.004	0.000087%		-
Therapeutic response decreased	08.06.01.016	0.000262%		-
Therapeutic response unexpected	08.06.01.001	0.000182%		-
Thrombocytopenia	01.08.01.002	0.001800%		-
Thrombocytosis	01.08.02.001	0.000164%		-
Thrombophlebitis	24.01.02.001	-	-	-
Thrombotic microangiopathy	01.01.02.006; 20.01.07.004; 24.01.01.013	0.000262%		-
Thrombotic thrombocytopenic purpura	01.08.01.005; 23.06.01.011; 24.07.06.014	0.000070%
Thyroiditis	05.02.04.001	0.000070%		-
Tinnitus	04.04.01.002; 17.04.07.004	0.000210%
Tooth loss	07.09.09.001; 12.01.17.026	0.000105%		-
Toothache	07.09.06.001	0.000087%
Toxic encephalopathy	12.03.01.027; 17.13.01.004	0.000052%		-
Toxic epidermal necrolysis	10.01.01.006; 11.07.01.006; 12.03.01.015; 23.03.01.008	0.000105%
Transplant rejection	10.02.03.002; 12.02.05.022	0.000140%		-

The 21th Page First Pre 21 22 23 24 25 Next Last Total 36 Pages